merck & co. inc. - MRK

MRK

Close Chg Chg %
115.86 -0.24 -0.20%

Closed Market

115.63

-0.24 (0.20%)

Volume: 7.11M

Last Updated:

Mar 13, 2026, 3:59 PM EDT

Company Overview: merck & co. inc. - MRK

MRK Key Data

Open

$116.41

Day Range

115.53 - 117.89

52 Week Range

73.31 - 125.14

Market Cap

$286.57B

Shares Outstanding

2.47B

Public Float

2.47B

Beta

0.28

Rev. Per Employee

N/A

P/E Ratio

15.92

EPS

$7.29

Yield

282.98%

Dividend

$0.85

EX-DIVIDEND DATE

Mar 16, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

9.92M

 

MRK Performance

1 Week
 
-0.16%
 
1 Month
 
-4.78%
 
3 Months
 
15.26%
 
1 Year
 
22.25%
 
5 Years
 
54.97%
 

MRK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About merck & co. inc. - MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

MRK At a Glance

Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, New Jersey 07065
Phone 1-908-740-4000 Revenue 64.93B
Industry Pharmaceuticals: Major Net Income 18.25B
Sector Health Technology 2025 Sales Growth 1.49%
Fiscal Year-end 12 / 2026 Employees 75,000
View SEC Filings

MRK Valuation

P/E Current 15.919
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.456
Price to Sales Ratio 4.064
Price to Book Ratio 4.952
Price to Cash Flow Ratio 16.02
Enterprise Value to EBITDA 10.223
Enterprise Value to Sales 4.617
Total Debt to Enterprise Value 0.169

MRK Efficiency

Revenue/Employee 865,680.00
Income Per Employee 243,386.667
Receivables Turnover 5.121
Total Asset Turnover 0.511

MRK Liquidity

Current Ratio 1.536
Quick Ratio 1.301
Cash Ratio 0.519

MRK Profitability

Gross Margin 71.976
Operating Margin 36.173
Pretax Margin 32.448
Net Margin 28.115
Return on Assets 14.375
Return on Equity 36.907
Return on Total Capital 17.698
Return on Invested Capital 20.069

MRK Capital Structure

Total Debt to Total Equity 96.061
Total Debt to Total Capital 48.996
Total Debt to Total Assets 36.922
Long-Term Debt to Equity 90.581
Long-Term Debt to Total Capital 46.20
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Merck & Co. Inc. - MRK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
58.47B 59.87B 63.97B 64.93B
Sales Growth
+19.56% +2.39% +6.85% +1.49%
Cost of Goods Sold (COGS) incl D&A
17.21B 15.98B 16.80B 18.20B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.91B 3.87B 4.50B 5.84B
Depreciation
1.82B 1.83B 2.10B 3.04B
Amortization of Intangibles
2.08B 2.04B 2.40B 2.79B
COGS Growth
+27.77% -7.14% +5.16% +8.29%
Gross Income
41.27B 43.89B 47.17B 46.73B
Gross Income Growth
+16.44% +6.37% +7.47% -0.93%
Gross Profit Margin
+70.57% +73.31% +73.74% +71.98%
2022 2023 2024 2025 5-year trend
SG&A Expense
21.77B 40.91B 26.53B 23.25B
Research & Development
11.82B 30.53B 15.79B 12.51B
Other SG&A
9.95B 10.38B 10.73B 10.73B
SGA Growth
+9.81% +87.96% -35.16% -12.37%
Other Operating Expense
- - - -
-
Unusual Expense
2.27B 1.03B 1.18B 1.70B
EBIT after Unusual Expense
17.23B 1.95B 19.46B 21.78B
Non Operating Income/Expense
174.00M 1.08B 1.74B 642.00M
Non-Operating Interest Income
157.00M 365.00M 415.00M 343.00M
Equity in Earnings of Affiliates
(1.42B) (106.00M) (29.00M) (55.00M)
Interest Expense
962.00M 1.15B 1.27B 1.36B
Interest Expense Growth
+19.35% +19.13% +10.91% +6.77%
Gross Interest Expense
962.00M 1.15B 1.27B 1.36B
Interest Capitalized
- - - -
-
Pretax Income
16.44B 1.89B 19.94B 21.07B
Pretax Income Growth
+18.48% -88.51% +955.37% +5.67%
Pretax Margin
+28.12% +3.16% +31.16% +32.45%
Income Tax
1.92B 1.51B 2.80B 2.80B
Income Tax - Current - Domestic
2.32B 976.00M 929.00M 403.00M
Income Tax - Current - Foreign
1.16B 2.44B 3.12B 4.07B
Income Tax - Deferred - Domestic
(1.64B) (1.67B) (1.46B) (1.59B)
Income Tax - Deferred - Foreign
71.00M (233.00M) 212.00M (83.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(1.42B) (106.00M) (29.00M) (55.00M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
14.53B 377.00M 17.13B 18.26B
Minority Interest Expense
7.00M 12.00M 16.00M 9.00M
Net Income
14.52B 365.00M 17.12B 18.25B
Net Income Growth
+17.61% -97.49% +4,589.59% +6.64%
Net Margin Growth
+24.83% +0.61% +26.76% +28.12%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
14.52B 365.00M 17.12B 18.25B
Preferred Dividends
- - - -
-
Net Income Available to Common
14.52B 365.00M 17.12B 18.25B
EPS (Basic)
5.7342 0.1439 6.7603 7.2958
EPS (Basic) Growth
+11.18% -97.49% +4,597.92% +7.92%
Basic Shares Outstanding
2.53B 2.54B 2.53B 2.50B
EPS (Diluted)
5.7116 0.1433 6.7363 7.2812
EPS (Diluted) Growth
+11.09% -97.49% +4,600.84% +8.09%
Diluted Shares Outstanding
2.54B 2.55B 2.54B 2.51B
EBITDA
23.41B 6.85B 25.14B 29.32B
EBITDA Growth
+24.30% -70.72% +266.84% +16.63%
EBITDA Margin
+40.04% +11.45% +39.30% +45.17%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 128.40
Number of Ratings 31 Current Quarters Estimate -1.55
FY Report Date 03 / 2026 Current Year's Estimate 5.118
Last Quarter’s Earnings 2.04 Median PE on CY Estimate N/A
Year Ago Earnings 8.98 Next Fiscal Year Estimate 9.685
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 18 25 24
Mean Estimate -1.55 2.11 5.12 9.69
High Estimates -1.36 2.27 5.23 10.43
Low Estimate -2.16 1.91 5.00 9.02
Coefficient of Variance -11.71 4.01 0.98 4.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 13
OVERWEIGHT 3 3 2
HOLD 12 12 12
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Merck & Co. Inc. - MRK

Date Name Shares Transaction Value
Feb 13, 2026 Chirfi Guindo Chief Marketing Officer 60,615 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $121.46 per share 7,362,297.90
Jan 29, 2026 Joseph Romanelli President, Human Health Int?l 28,739 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 3,086,568.60
Jan 29, 2026 David Michael Williams EVP,Chief Info&Digital Officer 30,838 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 3,312,001.20
Jan 29, 2026 Dalton E. Smart SVP Fin. - Global Controller 10,605 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 1,138,977.00
Jan 29, 2026 Jennifer Zachary EVP, General Counsel 68,916 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 7,401,578.40
Jan 29, 2026 Sanat Chattopadhyay Exe V-P & Pres. MMD 13,880 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 1,490,712.00
Jan 29, 2026 Johannes Jacobus Oosthuizen President, U.S. Market 36,197 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 3,887,557.80
Jan 29, 2026 Caroline A. Litchfield EVP & CFO 90,192 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 9,686,620.80
Jan 29, 2026 Richard R. DeLuca EVP&Pres, Merck Animal Heallth 197,859 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 21,250,056.60
Jan 29, 2026 Dean Y. Li Executive VP & President, MRL 102,270 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 10,983,798.00
Jan 29, 2026 Robert M. Davis Chairman, CEO & President; Director 491,036 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 52,737,266.40
Jan 6, 2026 Mary Ellen Coe Director 29,232 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Thomas Henry Glocer Director 103,425 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Paul B. Rothman Director 31,991 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Stephen L. Mayo Director 12,540 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Kathy J. Warden Director 15,504 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Douglas M. Baker Director 9,344 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Risa J. Lavizzo-Mourey Director 15,367 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Patricia Fiorello Russo Director 58,523 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Inge G. Thulin Director 24,764 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Merck & Co. Inc. in the News